Dr. Abou-Alfa on the FDA Approval of Cabozantinib in HCC

January 20, 2019

Ghassan K. Abou-Alfa, MD

In Partnership With:

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).